LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - Generic Drug Details

What are the generic sources for leuprolide acetate; norethindrone acetate and what is the scope of freedom to operate?

Leuprolide acetate; norethindrone acetate is the generic ingredient in one branded drug marketed by Abbvie Endocrine and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Clinical Trials:	1
DailyMed Link:	LEUPROLIDE ACETATE; NORETHINDRONE ACETATE at DailyMed

Recent Clinical Trials for LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 3

See all LEUPROLIDE ACETATE; NORETHINDRONE ACETATE clinical trials

US Patents and Regulatory Information for LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie Endocrine	LUPANETA PACK	leuprolide acetate; norethindrone acetate	INJECTABLE, TABLET;INTRAMUSCULAR, ORAL	203696-002	Dec 14, 2012		DISCN	Yes	No
Abbvie Endocrine	LUPANETA PACK	leuprolide acetate; norethindrone acetate	INJECTABLE, TABLET;INTRAMUSCULAR, ORAL	203696-001	Dec 14, 2012		DISCN	Yes	No

Expired US Patents for LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie Endocrine	LUPANETA PACK	leuprolide acetate; norethindrone acetate	INJECTABLE, TABLET;INTRAMUSCULAR, ORAL	203696-001	Dec 14, 2012
Abbvie Endocrine	LUPANETA PACK	leuprolide acetate; norethindrone acetate	INJECTABLE, TABLET;INTRAMUSCULAR, ORAL	203696-002	Dec 14, 2012

Leuprolide Acetate and Norethindrone Acetate Market Dynamics, Patent Risk, and Financial Trajectory

Last updated: September 7, 2026

Leuprolide acetate plus norethindrone acetate is an endometriosis treatment strategy built around monthly or three-monthly GnRH agonist suppression with norethindrone add-back therapy. In the United States, the combination is commercialized primarily through AbbVie’s Lupaneta Pack, which contains Lupron Depot leuprolide acetate and norethindrone acetate tablets. The market is mature, patent exposure is largely post-exclusivity, and commercial pressure comes from generic leuprolide products, procedural alternatives, and newer oral GnRH therapies such as relugolix combinations.

Lupron remains commercially relevant, but AbbVie does not disclose a separate current revenue line for Lupaneta Pack or Lupron Depot in its consolidated reporting. The product’s financial trajectory is therefore best assessed through historical product sales, prescription trends, market share, pricing, and erosion from generic and oral competitors rather than through a separately reported revenue forecast.

What is the leuprolide acetate and norethindrone acetate combination?

Leuprolide acetate is a gonadotropin-releasing hormone agonist. Continuous administration suppresses ovarian estrogen production after an initial stimulation phase. Norethindrone acetate is administered as add-back therapy to reduce bone mineral density loss and vasomotor symptoms associated with prolonged hypoestrogenism.

The U.S. Lupaneta Pack indication is the initial management of painful symptoms associated with endometriosis, with or without surgical treatment. The labeled treatment duration is limited to 12 months because of bone mineral density concerns associated with leuprolide therapy. Norethindrone acetate is administered at 5 mg daily during treatment with the depot formulation. [1]

How does Lupaneta Pack differ from Lupron Depot?

Product	Active ingredients	Primary use	Delivery	Commercial position
Lupron Depot	Leuprolide acetate	Endometriosis, uterine fibroids, prostate cancer, central precocious puberty, depending on strength	Intramuscular depot injection	Broad platform product
Lupaneta Pack	Leuprolide acetate plus norethindrone acetate	Endometriosis	Depot injection plus oral tablet	Combination packaging and add-back regimen
Norethindrone acetate generic	Norethindrone acetate	Add-back therapy and other hormonal indications	Oral tablet	Low-cost generic component
Orilissa	Elagolix	Endometriosis pain	Oral tablet	Competing oral GnRH antagonist
Myfembree	Relugolix, estradiol, norethindrone acetate	Endometriosis and uterine fibroids	Oral tablet	Oral combination competitor

Lupaneta Pack is not a new chemical combination with a separate long-duration exclusivity profile comparable to a novel molecular entity. Its value is linked to the clinical and commercial positioning of the leuprolide depot regimen and the convenience of co-packaging.

What is the FDA regulatory status of leuprolide acetate and norethindrone acetate?

The FDA approved Lupaneta Pack in October 2012 for endometriosis-associated pain. The product combines an established leuprolide depot product with norethindrone acetate add-back therapy. [2]

Lupron Depot has multiple strengths and indications. Product-specific regulatory status depends on the dosage form, strength, route, and indication. The principal products include 1-month and 3-month depot presentations, with separate prostate cancer, uterine fibroid, endometriosis, and pediatric formulations.

The FDA’s regulatory framework treats leuprolide depot products as pharmaceutical products rather than biologics. Biosimilar pathways therefore do not apply. Competitive products must generally pursue abbreviated or full drug applications depending on formulation complexity and reference-product requirements.

What is the Orange Book status?

The Orange Book status must be evaluated by product and application number. Lupron Depot products are associated with legacy NDA listings, while Lupaneta Pack has its own product-specific regulatory record. Orange Book protection for older leuprolide products is materially different from the remaining commercial protection of the combination packaging.

The principal legal distinction is between:

• Patent protection listed for the reference product;
• FDA regulatory exclusivity;
• Formulation and device protection;
• Manufacturing know-how;
• Market access and physician familiarity.

FDA approval does not prevent all generic competition after listed patents expire. A generic applicant may file an ANDA with a Paragraph IV certification against listed patents or wait for patent expiry.

When does leuprolide acetate lose exclusivity?

Leuprolide acetate lost the characteristics of a single, fully protected franchise years ago because the original compound and early product patents are expired or near the end of their enforceable lives. Exclusivity now depends on individual depot strengths, indications, formulations, manufacturing methods, and listed patents.

Protection category	Commercial assessment
Original leuprolide compound	Historical protection; no longer the principal barrier
Early Lupron formulations	Largely mature or expired
Depot microsphere technology	Can create technical and regulatory barriers, but does not create broad product exclusivity by itself
Lupaneta Pack combination	Limited incremental protection compared with the underlying products
Norethindrone acetate	Mature generic ingredient
Manufacturing process	Potentially relevant where depot particle size, release profile, sterility, or scale-up is difficult
FDA exclusivity	Historical exclusivity periods have expired for the established products

Exact expiration dates vary by NDA, strength, patent listing, pediatric extension, and any applicable regulatory exclusivity. A single expiration date cannot accurately describe the entire leuprolide acetate franchise.

What patents protect Lupaneta Pack and Lupron Depot?

The commercially important patent estate is primarily historical and product-specific. Protection has covered leuprolide compositions, depot formulations, sustained-release delivery systems, dosing regimens, and manufacturing processes.

A patent analysis should separate four claim groups:

Depot formulation patents

These claims may cover biodegradable polymer microspheres, drug loading, release kinetics, particle-size distribution, and depot stability. They are the most relevant formulation claims for injectable generic competition.

Method-of-use patents

Use claims may address endometriosis, uterine fibroids, prostate cancer, central precocious puberty, dosing intervals, and add-back therapy. Their practical value depends on indication carve-outs and whether the generic label can omit protected uses.

Combination and co-packaging claims

Lupaneta Pack’s commercial differentiation is linked to the combined use of leuprolide and norethindrone acetate. Combination claims can be narrower than compound claims and may be vulnerable where the underlying ingredients are already known and the clinical regimen is obvious.

Manufacturing patents

Manufacturing rights may cover aseptic production, polymer encapsulation, reconstitution, syringe configuration, and release testing. These rights can delay or complicate entry even when composition patents have expired.

A reliable patent opinion requires a current Orange Book extraction, patent-family review, prosecution history, terminal-disclaimer analysis, and litigation search. Publicly available information supports a mature estate assessment, not a claim that every historical patent has the same expiration date or enforceability.

Which companies are challenging the leuprolide market?

Competition comes from several sources rather than one direct generic event.

Competitor group	Examples	Main competitive mechanism
Leuprolide generic suppliers	Injectable and depot manufacturers pursuing products by strength	Lower acquisition cost and payer substitution
Oral GnRH antagonists	AbbVie’s Orilissa; Myovant/Pfizer’s Myfembree	Oral administration and differentiated dosing
Other hormonal therapies	Progestins, combined hormonal contraceptives, aromatase-inhibitor regimens	Lower cost and established prescribing
Surgery	Laparoscopic excision or ablation	Potentially durable symptom management
Specialty pharmacies and hospitals	Institutional procurement channels	Contracting and price competition

The principal branded threat is not biosimilar substitution. It is migration from injectable GnRH agonists to oral GnRH antagonists and combination products.

What generic entry risks exist for leuprolide acetate?

Generic entry risk is moderate to high over the long term, but the timing depends on technical development.

Leuprolide acetate depot products are more difficult to copy than conventional oral tablets. Generic developers must reproduce:

• Active ingredient identity and potency;
• Depot particle size and polymer characteristics;
• Reconstitution behavior;
• Injection performance;
• Release profile;
• Stability and sterility;
• Clinical or pharmacokinetic comparability required by FDA.

These requirements raise development costs and can reduce the number of entrants. The market may therefore experience limited competition even after core patents expire.

Norethindrone acetate has substantially lower entry barriers. It is a mature oral generic product, and its standalone economics are weak. Its role in Lupaneta Pack is clinically important but not a source of meaningful standalone pricing power.

How strong is the patent estate for leuprolide acetate and norethindrone acetate?

The estate is stronger operationally than legally.

Factor	Assessment
Compound patent strength	Low for mature ingredients
Depot formulation complexity	Moderate to high
Combination-patent durability	Low to moderate
Manufacturing barriers	Moderate
Regulatory substitution risk	High
Physician familiarity	Strong incumbent advantage
Payer pricing protection	Limited
Biosimilar protection	Not applicable

The central barrier is the complexity of the injectable depot, not broad exclusion from the active ingredients. A generic entrant with a technically robust product can pressure pricing, but development and manufacturing capacity may limit the number of approved competitors.

What is the financial trajectory for leuprolide acetate and Lupaneta Pack?

Lupron’s financial trajectory is mature-to-declining. The product previously benefited from broad indications, recurring depot administration, oncology demand, and long-standing physician recognition. Revenue pressure has increased as:

1. Core patents and regulatory exclusivity have aged;
2. Generic or lower-cost leuprolide alternatives have expanded;
3. Oral GnRH therapies have entered endometriosis and fibroid markets;
4. Payers have increased utilization management;
5. Treatment has shifted toward targeted surgery and chronic oral regimens.

AbbVie does not separately report current Lupaneta Pack revenue in its annual reports. Lupron is not presented as a major standalone growth driver in the company’s current financial disclosures. [3] Its economic contribution is therefore likely concentrated in a mature cash-flow base rather than a high-growth franchise.

Revenue exposure by market segment

Segment	Outlook
Endometriosis	Declining or pressured due to oral alternatives and treatment switching
Uterine fibroids	Pressure from oral GnRH combinations and procedural options
Prostate cancer	Durable demand, but subject to oncology treatment evolution and generic competition
Central precocious puberty	Smaller, specialized market with greater clinical stickiness
Norethindrone acetate	Commodity-like pricing and limited incremental revenue

The financial profile differs by indication. Prostate cancer and pediatric use may have stronger treatment continuity than endometriosis, where oral alternatives and multiple hormonal regimens create greater switching risk.

What patent litigation and Paragraph IV activity affect the products?

There is no single current litigation event that defines the commercial outlook for the entire leuprolide-and-norethindrone market. Patent litigation must be reviewed by NDA, strength, formulation, and ANDA applicant.

Paragraph IV risk is highest where a generic applicant seeks approval before expiry of listed depot patents. Potential litigation issues include:

• Whether the generic reproduces a protected polymer system;
• Whether the applicant’s label includes a patented indication;
• Whether a method-of-use patent is vulnerable to a skinny-label strategy;
• Whether manufacturing claims are infringed;
• Whether patents are properly listed in the Orange Book;
• Whether a patent is invalid for obviousness or lack of written description.

Settlement agreements, if any, must be assessed for entry dates, licensed manufacturing rights, authorized-generic provisions, supply obligations, and restrictions on competing dosage strengths. The commercial effect of a settlement can exceed the nominal patent expiry date because an early-entry license may establish a controlled duopoly.

How does leuprolide plus norethindrone compare with Myfembree and Orilissa?

Attribute	Leuprolide plus norethindrone	Myfembree	Orilissa
Mechanism	GnRH agonist with add-back	GnRH antagonist with estrogen/progestin add-back	GnRH antagonist
Administration	Injection plus daily tablet	Daily oral tablet	Daily oral tablet
Onset	Initial hormonal flare can occur	Rapid suppression without agonist flare	Rapid suppression without agonist flare
Key commercial advantage	Established depot efficacy and physician familiarity	Oral convenience and integrated add-back	Oral convenience
Main disadvantage	Injection, flare, clinic administration, mature patent estate	Newer product with payer and adoption hurdles	Limited duration and hypoestrogenic effects
Pricing risk	High	Moderate	Moderate to high
Generic exposure	Increasing	More dependent on remaining patents	More dependent on remaining patents

The oral products have a structural convenience advantage. Leuprolide retains value where depot adherence, established oncology use, or clinician preference outweighs the burden of injection.

What geographic coverage and manufacturing barriers matter?

The United States is the most commercially important reference market for Lupaneta Pack and Lupron Depot. Patent and regulatory positions differ across Europe, Japan, China, and other jurisdictions. National patent expiry, supplementary protection certificates, pediatric extensions, regulatory data exclusivity, procurement systems, and reimbursement rules can produce different entry dates.

Manufacturing remains a meaningful barrier. Depot leuprolide requires specialized peptide production, polymer encapsulation, aseptic filling, validated release testing, and reliable reconstitution performance. A company may hold no enforceable composition patent yet retain an economic advantage through manufacturing scale, supplier qualification, quality systems, and clinical familiarity.

Key Takeaways

• Leuprolide acetate plus norethindrone acetate is a mature endometriosis regimen commercialized through Lupaneta Pack.
• Leuprolide’s core compound protection is no longer the principal commercial barrier.
• Depot formulation, manufacturing, sterility, and release-profile requirements can delay generic entry.
• Norethindrone acetate is a mature generic ingredient with limited pricing power.
• No biosimilar pathway applies because leuprolide is a pharmaceutical peptide product, not a biologic reference product.
• Oral GnRH antagonists, especially Myfembree and Orilissa, are the principal branded competitive threat.
• AbbVie does not separately disclose current Lupaneta Pack or Lupron revenue, making the financial trajectory a mature-to-declining franchise assessment rather than a separately reported forecast.
• Paragraph IV risk depends on individual depot strengths, listed patents, indication claims, and generic formulation design.
• The strongest remaining commercial defenses are manufacturing capability, regulatory execution, clinical familiarity, and channel access.

FAQs

Is Lupaneta Pack still commercially protected?

Lupaneta Pack may retain product-specific listed patents or regulatory protections depending on the relevant NDA and formulation, but the broader leuprolide franchise is mature. Protection should be assessed by strength, dosage form, and Orange Book listing.

Can a generic company copy leuprolide depot without copying Lupron’s manufacturing process?

Yes. A generic applicant can use a different non-infringing process if it produces a product meeting FDA requirements. Process patents and formulation claims can still create litigation risk.

Is norethindrone acetate responsible for the commercial value of Lupaneta Pack?

No. Norethindrone acetate is a low-cost generic component. The commercial value comes mainly from the leuprolide depot, the treatment protocol, clinical familiarity, and co-packaged convenience.

Will Myfembree replace leuprolide acetate for endometriosis?

Myfembree can take share because it is oral and includes integrated add-back therapy. It is unlikely to eliminate leuprolide because oncology, pediatric, procedural, and depot-adherence uses remain differentiated.

What is the most important investment risk for leuprolide acetate?

The main risk is cumulative erosion from generic depot products, oral GnRH competitors, payer restrictions, and declining use of injectable therapy. The key offset is the technical difficulty of reproducing a long-acting sterile depot product.

References

1. U.S. Food and Drug Administration. (2022). Lupaneta Pack: Prescribing information.
2. U.S. Food and Drug Administration. (2012). FDA approves Lupaneta Pack for endometriosis-associated pain.
3. AbbVie Inc. (2024). 2023 annual report.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations.